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Background: Micro-costing is a cost estimation method that allows for precise assessment of the economic costs
of health interventions. It has been demonstrated to be particularly useful for estimating the costs of new
interventions, for interventions with large variability across providers, and for estimating the true costs to the health
system and to society. However, existing guidelines for economic evaluations do not provide sufficient detail of the
methods and techniques to use when conducting micro-costing analyses. Therefore, the purpose of this study is to
review the current literature on micro-costing studies of health and medical interventions, strategies, and programs
to assess the variation in micro-costing methodology and the quality of existing studies. This will inform current
practice in conducting and reporting micro-costing studies and lead to greater standardization in methodology in
the future.
Methods/Design: We will perform a systematic review of the current literature on micro-costing studies of health
and medical interventions, strategies, and programs. Using rigorously designed search strategies, we will search
Ovid MEDLINE, EconLit, BIOSIS Previews, Embase, Scopus, and the National Health Service Economic Evaluation
Database (NHS EED) to identify relevant English-language articles. These searches will be supplemented by a review
of the references of relevant articles identified. Two members of the review team will independently extract detailed
information on the design and characteristics of each included article using a standardized data collection form. A
third reviewer will be consulted to resolve discrepancies. We will use checklists that have been developed for critical
appraisal of health economics studies to evaluate the quality and potential risk of bias of included studies.
Discussion: This systematic review will provide useful information to help standardize the methods and techniques
for conducting and reporting micro-costing studies in research, which can improve the quality and transparency of
future studies and enhance comparability and interpretation of findings. In the long run, these efforts will facilitate
clinical and health policy decision-making about resource allocation.
Trial registration: Systematic review registration: PROSPERO CRD42014007453.
Keywords: Systematic review, Micro-costing, Health, Economic evaluation, Cost analysisBackground
Micro-costing is a cost estimation method that involves
the ‘direct enumeration and costing out of every input
consumed in the treatment of a particular patient’ [1]. In
contrast to gross-costing studies that often reflect reim-
bursement amounts or charges, micro-costing improves
precision in cost estimation and reflects actual resource
use and economic costs by collecting detailed data on* Correspondence: xiao.xu@yale.edu
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Unlike gross-costing methods, which estimate average
levels and are unable to provide transparent and consist-
ent estimates, micro-costing findings reflect the true
costs to the healthcare system and to society. Previous
research has shown that using micro-costing methods to
measure important cost components helps improve the
validity and reliability of total cost estimates for hospital
services, and for diagnostic or treatment interventions
where costs are not available or evolving [2-5]. It is particu-
larly useful for estimating the costs of new interventions orThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Search strategy for MEDLINE
1. (microcost$ or micro-cost$).mp.
2. bottom-up.mp.
3. “costs and cost analysis”/or health care costs/or health expenditures/
4. 2 and 3
5. (bottom-up adj5 cost$).mp.
6. (bottom-up adj5 accounting).mp.
7. (activity-based adj5 accounting).mp.
8. (activity-based adj5 cost$).mp.
9. 1 or 4 or 5 or 6 or 7 or 8
10. limit 9 to english language
11. limit 10 to journal article
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aggregate costs [6,7].
The widespread concern about increasing healthcare
costs in the USA, as well as in other countries, has
prompted growing interest in studying the cost, cost-
effectiveness, and cost-benefit of health interventions. It
is essential that the costs of health interventions be
assessed rigorously in order to inform efficient resource
allocation. Cost estimation is the foundation for any eco-
nomic evaluation. The U.S. Panel on Cost Effectiveness in
Health and Medicine has recommended micro-costing as
the preferred approach to cost estimation when the alter-
native gross-costing estimation could cause bias [1]. How-
ever, existing guidelines for economic evaluations do not
provide sufficient detail for the methods and techniques
to use when conducting micro-costing analyses [6].
In this study, we propose to review the current literature
on micro-costing studies of health and medical interven-
tions, strategies, and programs to assess how widely and
variably micro-costing methodology has been used and
the quality of existing studies. Findings from this review
will help identify gaps in current application of micro-
costing analyses, inform the development of guidelines for
micro-costing methodology and a checklist for conducting
and reporting micro-costing studies, and ultimately im-
prove the transparency and comparability of future micro-
costing studies.
Methods/Design
The design of this systematic review follows recommen-
dations in the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement [8], guid-
ance from the Campbell and Cochrane Economics Methods
Group on incorporating economics evidence in systematic
reviews [9], and criteria in the Assessment of Multiple
Systematic Reviews (AMSTAR) [10]. To help guide the
development of the protocol, we conducted a preliminary
assessment of the literature using a pilot list of search
terms and a single database (PubMed) from March to July
2013. This preliminary assessment helped us identify the
terms that authors use when referencing micro-costing
methods, the type of health interventions evaluated, the
study settings involved, and the types of analysis con-
ducted. Based on results from this preliminary assessment,
we refined our search terms, the study selection criteria,
the data items to be extracted, and the analytic framework
needed to comprehensively evaluate the quality of these
studies. Details of our final study protocol are provided
below.
Objective/research question
The purpose of this study is to address the question: How
has micro-costing methodology been used in studying
health and medical interventions, strategies, and programs?We will take a systematic approach by reviewing micro-
costing studies in the health and medical literature to
understand both the scope (how widely and variably has
this methodology been used) and the quality (how well
has this methodology been applied and reported) of these
studies. The interventions, strategies and programs may
include preventive, diagnostic, and treatment approaches
and technologies, as well as public health initiatives.
Protocol and registration
This systematic review has been registered at the Inter-
national Prospective Register of Systematic Reviews
(PROSPERO) (registration #: CRD42014007453) [11].
Information sources and search strategy
We will search Ovid MEDLINE, EconLit, BIOSIS Previews,
Embase, Scopus, and the National Health Service Economic
Evaluation Database (NHS EED) to identify relevant
English-language articles. This list of bibliographic da-
tabases was determined after careful scoping searches
and assessments of the 2011 Health Economic Core
Library Recommendations by the U.S. National Library of
Medicine [12].
We will use the search strategy outlined in Table 1 for
MEDLINE. The search strategies for other databases will
be similar but tailored slightly to fit each specific data-
base. Search results from the various databases will be
combined and results will be de-duplicated. This will be
supplemented by a review of the references of relevant
articles identified. Auto-alerts will provide literature up-
dates while the data are being analyzed.
Eligibility criteria and study selection
We will include studies that meet the following criteria:
(1) involve original economic analysis of data; (2) involve
a health- or healthcare-related intervention, strategy, or
program; and (3) involve the use of micro-costing meth-
odology as defined by Gold et al. [1] that involves the
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sumed in the treatment of a particular patient’. Economic
analysis will include both full economic evaluations and
partial economic evaluations, as well as randomized trials
or other types of single effectiveness studies that evaluate
cost of care [9]. We will operationalize the Gold et al. [1]
definition for micro-costing by including studies that in-
volve: (1) patient-level data on direct enumeration and
costing of all inputs consumed with clear delineation of
unit cost information; or (2) program-level direct enumer-
ation and costing of all inputs consumed (with clear delin-
eation of unit cost information) which was then divided
across individual participants. Because complete micro-
costing may not be feasible in many situations, we will
also consider studies that predominantly used micro-
costing in their cost estimation. We will exclude studies
published only as abstracts, in a language other than Eng-
lish, reflecting biomedical or laboratory research, report-
ing quantities of resource utilization (for example, length
of stay) rather than costs, focusing on identifying cost pre-
dictors (for example, analyze impact of patient sociodemo-
graphics on cost of care) rather than evaluating costs, or
only partially applying the micro-costing methodology (for
example, use a combination of micro-costing and gross-
costing). We will also exclude reviews, conceptual papers,
commentaries, letters, editorials, and papers that only re-
port a study’s methodology without results.
Search results from the various databases will be
combined and results will be de-duplicated. A two-phaseTable 2 Items on article screening form
Phase 1 screening:
Full length article (yes/no)
Original research article (yes/no)
Economic evaluation (yes/no)
Health- or healthcare-related (yes
Other reason for exclusion (yes/n
All phase 1 screening criteria met
Phase 2 screening (if all phase 1 screening criteria are met):
Costing methods clear (yes/no)
Applied gross-costing (entirely gr
Applied micro-costing (yes, no, or
Extent of micro-costing (if micro-c
entire study or for part of the stu
Type of micro-costing (if micro-co
consumed; program-level direct e
participant; and so on.
Applied other costing methods (y
Whether authors referred to their
Whether to include the article in
Any additional notes about this ascreening process will be implemented (Table 2). The first
phase will screen for full-length, original research arti-
cles that involved economic evaluation of a health- or
healthcare-related topic. Then, for articles that fulfill the
criteria from the first phase screening, we will assess the
type of costing methods used and the extent to which
micro-costing technique was applied in the cost estima-
tion. This detailed screening will allow us to categorize,
summarize, and report reasons for excluded studies. More-
over, we will be able to provide information on the nature
of articles that involve some enumeration of resource
utilization and unit cost data but do not fully meet the def-
inition of micro-costing methodology [1] (for example,
direct enumeration and unit cost data for some inputs
consumed plus gross-costing or additional costing meth-
odologies for other cost components).
The screening will be based on inspection of study ti-
tles, abstracts, and full-text articles. Evaluation of full-
text articles will be important because abstracts include
only limited descriptions of study design and often can-
not provide sufficient detail about a study’s cost valu-
ation methodology. All identified articles from the initial
search will be independently reviewed by two members
of the review team to determine their appropriateness
for inclusion. Any disagreements will be discussed and
resolved by consensus. If a disagreement cannot be re-
solved, a third researcher will be consulted to help re-
solve disagreement and determine whether the article is
suitable for inclusion./no)
o, and if yes, specify the reason)
(yes/no)
oss-costing, partial gross-costing, no gross-costing, or not clear)
not clear)
osting used): for example, whether micro-costing was used for the
dy
sting used): patient-level direct enumeration and unit cost of all inputs
numeration and unit cost of all inputs consumed, then allocated to each
es, no, or not clear, and if yes, specify the methods used)
study as micro-costing (yes/no)
final data extraction (yes/no)
rticle
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For each included article, we will extract detailed infor-
mation on its characteristics using a standardized data
collection form. The International Society for Pharma-
coeconomics and Outcomes Research (ISPOR) recently
issued the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) guidelines that consoli-
dated and updated prior checklists for reporting of
health economic evaluations and are endorsed by 10 bio-
medical journals [13]. Our data items will be selected
based on the CHEERS guidelines [13], guidance from
the Campbell and Cochrane Economics Methods Group
on incorporating economics evidence in systematic re-
views [9], and our previous experience with systematic
reviews of health economics studies and with micro-
costing studies [5,14-18].
A draft list of data items is presented in Table 3. We
specifically tailored this list to suit the aim of this review,
that is, to focus on each study’s cost estimation methods.
For example, we plan to record whether the study separ-
ately reported input utilization quantity and unit cost
data which are important for the conduct and interpret-
ation of micro-costing analysis [7], method of quantity
data collection used (for example, time-motion study, pa-
tient self-report, cost-accounting database, or provider/
staff interview), and method of unit cost data collection
(for example, invoice amount, or standard fee schedule).
Any additional features of a study that deserve consider-
ation when evaluating its quality will be noted in a ‘notes’
data field. We will first pilot a data collection form con-
taining these data items and modify/refine it as needed
prior to its final use.
Data collection process for included articles
For each included article, two members of the review
team will independently extract the data items using the
data collection form described above. Disagreements will
be discussed and resolved. If disagreements cannot be
resolved, a third researcher will be consulted to help de-
termine the most appropriate answer.
Assessment of study quality and risk of bias in individual
studies
In order to assess the quality and potential risk of bias
in individual studies, we will critically assess the quality
of each included study. This will be performed by using
checklists that have been developed for critical appraisal
of health economics studies. The Campbell and Cochrane
Economics Methods Group [9] has recommended the use
of three established checklists for appraising reporting and
methodological quality of economic evaluations: (1) the
Drummond checklist [19]; (2) the Evers checklist [20]; and
(3) the Phillips checklist [21]. A systematic review of qual-
ity assessment tools for conducting and reporting healtheconomic evaluations [22] also showed good evidence for
inter-rater reliability and test-retest reliability for the
Drummond checklist [19] and the Evers checklist [20].
Therefore, we will use the Drummond checklist [19] and
the Evers checklist [20] to evaluate the quality and risk of
bias for single effectiveness studies, and the Phillips check-
list [21] for assessing the quality and risk of bias for stud-
ies that relied on decision analytic modeling.
In addition, we will adopt the criteria developed by
Fukuda and Immanaka [23] to assess the transparency of
cost estimates in included economic evaluations. These
criteria categorize studies into transparency levels based
on whether each study clarifies what cost components
are included, whether the quantity and unit price of re-
sources are separately reported, and whether an estimate
of each cost component is reported. This also helps assess
the quality and potential risk of bias for each included
study. However, no checklist for appraising reporting and
methodological quality of micro-costing studies currently
exists.
Two members of the review team will independently
assess these checklists for each included article with a
consensus determined through discussion. If disagree-
ments cannot be resolved, a third researcher will be con-
sulted to help determine the most appropriate answer.
Data from these checklists will be reviewed, summa-
rized, and reported.
Summary measures and synthesis of results
Because we focus on reviewing and evaluating the meth-
odology and reporting quality of included studies, we will
not combine the findings across individual studies. There-
fore, there will not be a summary measure for this review.
Instead, we will critically assess the methodological
and reporting quality of included studies and provide tab-
ulations and narrative summaries. Data items extracted on
the screening and data collection forms will be reviewed,
categorized, and compared across studies. For included
articles, frequency of different methodological features
employed among the studies (for example, use of societal
perspective, separate reporting of input utilization and unit
cost data source, conducting of sensitivity analysis) will be
assessed. We will also summarize characteristics of the in-
cluded studies (for example, type of economic evaluation,
year of study). In particular, we will evaluate and report
the adoption/application of micro-costing methodology
across different disease categories (for example, infectious
and parasitic diseases, neoplasms, diseases of the circula-
tory system).
As recommended by the Campbell and Cochrane Eco-
nomics Methods Group [9], we will use tabulations and
narrative summary to report the study characteristics. Gaps
and limitations in the reporting and/or methodology of
these studies will be noted and discussed.
Table 3 Items on data collection form for included articles
1. Author
2. Year of publication
3. Journal name
4. Research topic and study questions
5. Disease category: disease name, disease classification based on International Classification of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) chapters (for example, infectious and parasitic diseases, neoplasms, diseases of the circulatory system, and so on)
6. Study intervention(s)
7. Comparator intervention(s)




12. Year(s) of study







20. Type of economic analysis: cost effectiveness analysis, cost utility analysis, cost benefit analysis, cost minimization analysis,
cost comparison analysis, cost outcome description, cost of illness study, and so on
21. Study type and design: randomized clinical trial, observational study, decision analytic modeling, other economic modeling, and so on
22. Economic outcome(s)
23. Health outcome(s)
24. Methods used to define effectiveness and preferences
25. Cost components included: personnel costs, consumables/materials/supplies cost, medication cost, facility cost, transportation
cost, productivity loss, and so on
26. Separate reporting of input utilization quantity and unit cost data
27. Method of quantity data collection: time-motion study, patient self-report, cost-accounting database, provider/staff interview, and so on
28. Method of unit cost data collection: invoice amount, hospital/clinic/provider price catalogue, national/regional/provincial/
hospital/insurer fee schedule, human resources/payroll record, and so on
29. Study assumption(s)
30. Sensitivity analyses performed: stochastic (probabilistic) sensitivity analysis, deterministic sensitivity analysis, or no sensitivity analysis
31. Whether the study referred to its own methodology as micro-costing
32. Comparison with other economic evaluation
33. Funding source: industry sponsored study, non-profit funding sources, no funding, or not specified
34. Conflict of interest: yes, no, or not reported
35. Notes (please record any additional features of the study that deserve consideration when evaluating its quality)
Xu et al. Systematic Reviews 2014, 3:47 Page 5 of 7
http://www.systematicreviewsjournal.com/content/3/1/47Additional analyses
We will carefully review articles captured in our system-
atic review that directly compare micro-costing with
other cost valuation methods, and appraise their find-
ings. This will allow us to report comparative informa-
tion on the performance of alternative cost estimation
methods, which can inform future research and policy
discussion.Risk of bias across studies
Risk of bias across studies is particularly relevant when a
systematic review combines evidence on treatment ef-
fects across multiple studies. However, our review seeks
to evaluate the methodological and reporting quality of
micro-costing studies, rather than the effect of any particu-
lar intervention, and will not combine results across stud-
ies. We will include studies across diseases and conditions,
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tions, strategies, and programs. Therefore, we expect that
the risk of bias across studies (for example, publication
bias, selective reporting bias) will have minimal impact
on our findings. Moreover, the traditional tools for asses-
sing publication bias (for example, funnel plots) or select-
ive reporting bias (for example, comparing outcomes
listed in the methods section with those reported in the
results section) have been designed for examining treat-
ment effect of interventions [6], which cannot be applied
to our study. Because of these considerations, our assess-
ment of the risk of bias across studies will be based on
evaluations of each study’s funding source (for example,
industry sponsored study, non-profit funding sources, no
funding, or not specified) [24] and the nature of disclosed
conflict of interest for the study.
Discussion
Micro-costing is a cost estimation method that enables
precise estimation of economic costs for health interven-
tions. With a growing interest in economic evaluations,
we expect to see an increasing number of studies adopting
this methodology. Therefore, standardizing the methods
and techniques for conducting and reporting a micro-
costing analysis is important. If researchers can establish
and follow a standardized method for conducting and
reporting micro-costing analyses, the quality and transpar-
ency of individual studies will be enhanced, and compar-
ability across studies and interpretation of findings will
improve. This systematic review will provide useful informa-
tion to facilitate this effort. Specific guidelines and check-
lists for conducting and reporting micro-costing studies
do not currently exist but can be developed and will help
inform clinical and health policy decision-making about
resource allocation in the long run.
We recognize that micro-costing has its own limita-
tions [1,6]. It is labor-intensive to collect such detailed
utilization and valuation data. The results may not be
widely generalizable, as the data may reflect only the prac-
tice at selected sites with specific populations. Hence, it is
not always feasible or desirable to use micro-costing in
economic evaluations. However, prior studies have demon-
strated the usefulness and importance of this methodology
in certain scenarios (for example, new interventions, exten-
sive variability across providers, and so on) [2-7,17,18] and
advances in electronic administrative databases (for ex-
ample, proprietary cost-accounting data systems) [6] por-
tend greater ease of individual-based data collection in the
future. The purpose of this systematic review is to provide
a critical assessment of how micro-costing has been used
in the current literature. This information can help set re-
search priorities for future economic evaluations and iden-
tify opportunities to improve the quality and reporting of
future studies when micro-costing is desired or needed.Abbreviations
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